The U.S. external analgesics market size was valued at USD 2.42 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 13.3% from 2023 to 2030. The market is driven by the increasing incidence of chronic & lifestyle diseases, leading to a higher demand for external analgesics. Investments from private and government organizations in pharmaceutical manufacturing and R&D activities for developing analgesic products are expected to influence market growth positively. The growing incidence of chronic disorders is main factor probable to contribute to the growth of the U.S. external analgesics market during the forecast period. The increasing incidence of lifestyle-related conditions such as obesity and diabetes has led to a higher need for muscle & nerve stimulators. For instance, as per Diabetes Research Institute Foundation (2022), diabetes affects a significant portion of the U.S. population. Approximately 37.3 million individuals, equivalent to 11.3% of the population, have diabetes. Around 28.7 million people, accounting for 28.5% of the population, have been diagnosed with the condition. The impact of diabetes is widespread and can be observed across various social, economic, and ethnic backgrounds. Patients tend to have diabetic neuropathy, making the disease one of the primary reasons for using electrical stimulators.
Further, the incidence of musculoskeletal disorders, such as arthritis, osteoarthritis, orthopedic degenerative disorders, and rheumatoid arthritis, is significantly increasing. This has augmented the prevalence of chronic pain among these individuals and the inability to perform routine tasks. For instance, according to Arthritis & Rheumatology, around 78 million adults are expected to be diagnosed with arthritis by 2040 in the U.S. This has fueled the demand for pain management stimulators to help manage chronic pain .
The demand for reduced hospital stays is increasing in the U.S. due to various factors shaping the healthcare industry. One significant driver is the growing emphasis on cost containment, which is compelling hospitals and healthcare providers to optimize resource utilization and reduce expenses. Prolonged hospital stays not only increase healthcare costs but also expose patients to a higher risk of complications and infections. Consequently, there is a growing focus on shifting certain treatments and services from inpatient to outpatient settings whenever possible.
The COVID-19 pandemic has had far-reaching effects on the management of chronic pain and the U.S. external analgesics market. The reduction of non-urgent procedures and the closure of specialty pain management centers disrupted patient care and increased home-based device usage which impacted the market. The shift toward telehealth and the increased demand for self-medication have influenced the choice of pain management methods, with medications gaining prominence over devices. Supply chain disruptions, e-commerce growth, and regulatory changes have also shaped the market landscape. As the world continues to navigate the pandemic, healthcare companies and regulatory bodies must adapt and innovate to meet the evolving needs of patients and consumers in the external analgesics industry.
Based on the product, the U.S. external analgesics market is segmented into hot/cold products, kinesiology tape, heating pads, TENS devices, and red light therapy products/infrared therapy products. The hot/cold products segment held the majority of the market share of 57.6% in the product segment in 2022. The segment is anticipated to witness remarkable growth during the forecast period. Growth of the segment can be attributed to its effectiveness in providing relief for a wide range of pain conditions.
The hot/cold product segment also has the advantage of being non-invasive and easy to use, making hot/cold products a convenient pain management solution for individuals seeking nonpharmacological approaches. With the growing demand for natural and self-directed pain management solutions, hot/cold products are expected to continue to dominate the U.S. external analgesics market.
On the other hand, kinesiology tape (KT) is anticipated to register the fastest growth rate of CAGR 13.3% over the forecast period. Further, kinesiology tape (KT) is a specialized adhesive tape that has gained significant popularity in the field of sports medicine and rehabilitation. KT is made from elastic cotton fabric with a wave-like acrylic adhesive, mimicking the properties of human skin. When applied correctly, it can enhance athletic performance, reduce pain, and aid in the recovery process.
The distribution channel is segmented into retail/brick-and-mortar, e-commerce, and others. Retail/brick-and-mortar held the majority of the share of 71.5% in the distribution channel segment in 2022. Retail/brick-and-mortar stores continue to dominate the U.S. external analgesics market because consumers typically prefer to browse and purchase these products in stores physically.
The COVID-19 pandemic played an important role in increasing self-care adaptation and helped elevate drug store sales of external analgesics. Top-performing brands such as Salonpas, Bio freeze, and GlaxoSmithKline shifted from prescriptions to OTC in 2020, making it the top-selling brand.
However, with the increasing adoption of e-commerce and the growth of online sales, retailers are now exploring omnichannel strategies to enhance their reach and better cater to the evolving needs and preferences of consumers. E-commerce is expected to grow at the fastest CAGR of 14.8% during the forecast period.
The industry is highly fragmented with the presence of various players. Key players and other companies catering to the market are adopting various strategies, including acquisitions, mergers, product launches, and collaborations, to maintain their market position. For instnace, in November 2022, Boston Scientific Corporation has announced its agreement to acquire Apollo Endosurgery, Inc. for a cash price of USD 10 per share, totaling approximately USD 615 million in enterprise value. Apollo Endosurgery offers a range of devices used in Endoluminal Surgery (ELS) procedures, addressing gastrointestinal defects & complications and aiding weight loss for obese patients. ELS provides a less invasive option with faster recovery and reduced surgical risks compared to open or laparoscopic surgery for gastrointestinal tract diseases and morbid obesity. Some of the prominent players in the U.S. external analgesics market include:
Boston Scientific Corporation
ICU Medical Inc.
OMRON Healthcare, Inc.
The revenue forecast in 2030
USD 6.7 billion
CAGR of 13.3% from 2023 to 2030
The base year for estimation
2018 - 2021
2023 - 2030
Revenue in USD million and CAGR from 2023 to 2030
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Product, distribution channel
Key companies profiled
Baxter; Boston Scientific Corporation; Enovis; Medtronic; ICU Medical Inc.; Abbott; Stryker; Nevro Corp.; OMRON Healthcare, Inc.
Free report customization (equivalent to up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. external analgesics market based on product and distribution channel:
Product Outlook (Revenue, USD Million, 2018 - 2030)
Red Light Therapy/ Infrared Therapy
Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
Retail/Brick & Mortar
b. The U.S. external analgesics market size was valued at USD 2.42 billion in 2022 and is expected to reach USD 2.78 billion in 2023.
b. The U.S. external analgesics market is expected to expand at a compound annual growth rate (CAGR) of 13.3% from 2023 to 2030 to reach USD 6.7 billion in 2030.
b. The hot/cold products segment held the majority of the market share of 57.6% in the product segment in 2022. The segment is anticipated to witness remarkable growth during the forecast period. Growth of the segment can be attributed to its effectiveness in providing relief for a wide range of pain conditions.
b. Some of the prominent players in the market include: • Baxter • Boston Scientific Corporation • Enovis • Medtronic • ICU Medical Inc. • Abbott • Stryker • Nevro Corp. • OMRON Healthcare, Inc.
b. The market is driven by the increasing incidence of chronic & lifestyle diseases, leading to a higher demand for external analgesics.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
"The quality of research they have done for us has been excellent."